ASX Announcements Due to legal restrictions, only residents of Australia and New Zealand may access ASX announcements that contain information or materials relating to any capital raising. Keyword Search Year None201920182017201620152014 Date Title 31 October 2019 Appendix 4C - quarterly 29 October 2019 Annual Report to shareholders 29 October 2019 Notice of General Meeting/Proxy Form 29 October 2019 Appendix 4G and Corporate Governance Statement 29 October 2019 Appointment of Joint Company Secretary 23 October 2019 Ceasing to be a substantial holder 23 October 2019 Change in substantial holding 17 October 2019 MSB and Lonza Enter GVHD Commercial Manufacturing Agreement 10 October 2019 Change in substantial holding 08 October 2019 Cleansing notice and Appendix 3B 08 October 2019 Change in substantial holding 03 October 2019 Mesoblast Raises A$75 Million 01 October 2019 Trading Halt 27 September 2019 Mesoblast Newsletter - Chronic Low Back Pain 10 September 2019 Analyst Call Presentation 10 September 2019 Analyst Call Details 10 September 2019 Grunenthal and MSB Enter Strategic Partnership for Back Pain 30 August 2019 Mesoblast Reports 2019 Full Year Results 30 August 2019 Mesoblast Reports on Annual Results 30 August 2019 Annual Financial Results Presentation 30 August 2019 Preliminary Final Report including Appendix 4E 27 August 2019 FDA Guidance on Clinical Pathway for LVAD Market Application 14 August 2019 Investigator-Initiated Trial Planned for Chronic GVHD 12 August 2019 Mesoblast Appoints Leading Pharma Industry Executive as CMO 31 July 2019 Appendix 4C - Quarterly, Strong Commercialization Revenues 25 July 2019 Circulation Research Highlights MSB Heart Failure Therapy 15 July 2019 Newsletter - Interview with GvHD Key Opinion Leader 12 July 2019 Change in substantial holding 11 July 2019 Appendix 3B 26 June 2019 Release of Shares from Voluntary Escrow 24 June 2019 FDA Grants Revascor Orphan Drug For End Stage CHF With LVADs 18 June 2019 High Economic Burden In Steroid-Refractory aGVHD 17 June 2019 MSB to Host Virtual Symposium with KOL on GvHD 11 June 2019 MSB Expands JCR Partnership To Brain Disease In Newborns 31 May 2019 Mesoblast Reports Financial Results and Operational Highlights for the Period Ended March 31, 2019 31 May 2019 MSB Provides Q3 Financial Results and Operational Highlights 31 May 2019 Third Quarter Results Presentation 31 May 2019 Third Quarter Financial Results on Form 6-K 30 May 2019 MSB Financial Results Webcast Timing 30 May 2019 Mesoblast Initiates Rolling Submission of BLA for GvHD 23 May 2019 Mesoblast Keynote Presentations at ISCT Annual Meeting 17 May 2019 Mesoblast to Present at RBC Global Healthcare Conference 30 April 2019 Appendix 4C - quarterly 16 April 2019 FDA Agrees to Rolling Review of Mesoblast BLA Submission 05 April 2019 Final Director's Interest Notice 05 April 2019 Presentation at Upcoming Global Life Science Conference 27 March 2019 MoU for Confirmatory Trial for GI Bleeding in LVAD Patients 25 March 2019 MSB Licensee Files For Skin Disease Marketing Approval 22 March 2019 Joseph R. Swedish Appointed Mesoblast Chairman 18 March 2019 Change in substantial holding 13 March 2019 Upcoming U.S. Investor Conferences 20 February 2019 Mesoblast Reports Financial Results and Operational Highlights for the First Half Ended December 31, 2018 21 February 2019 Mesoblast Provides Half Year Results and Corporate Update 21 February 2019 Half Year Financial Results Presentation 21 February 2019 Half Year Report and Accounts (including Appendix 4D) 19 February 2019 Final Patient Dosed in Mesoblast P3 Heart Failure Trial 19 February 2019 Mesoblast Newsletter on Advanced and End-Stage Heart Failure 11 February 2019 Change in substantial holding 31 January 2019 Appendix 4C - quarterly 14 January 2019 MSB Draws US$15 Million From Existing Facility 08 January 2019 MSB Highlights Key 2019 Priorities at U.S. Biotech Showcase 08 January 2019 Change of Director's Interest Notices 07 January 2019 P3 Trial of MSB's Cell Therapy in CHF Completes Recruitment 07 January 2019 Cleansing notice and Appendix 3B
